Compare Cassava Sciences Inc (FLNA) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Western Alliance Bancorporation — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Western Alliance Bancorporation trades at $81.46 (market cap $8.78B). The key difference: Western Alliance Bancorporation is far larger — about 183.9× Cassava Sciences Inc's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WAL | |
|---|---|---|
Market Cap | $47.75M | $8.78B |
Sector | Health | Financials |
52-Week High | $4.64 | $96.08 |
52-Week Low | $0.87 | $66.70 |
Enterprise Value | -$34.93M | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Western Alliance Bancorporation (WAL) trades at $81.39, up 0.06% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.08, net income margin of 25.43%, and consistent earnings beats in recent quarters. Recent developments include the launch of WA VenueX, a digital asset liquidity platform, and recognition as Arizona's top bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 15% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow and institutional selling, but revenue growth and profitability trends provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
